check_circleStudy Completed

Amyloid Cardiomyopathy

Bayer Identifier:
AG10-301
ClinicalTrials.gov Identifier:
NCT03860935
EudraCT Number:
Not Available
EU CT Number:
Not Available
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A
    -
    -

Trial summary

Enrollment Goal
N/A
Trial Dates
March 2019 - May 2023
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Acoramidis (BAY3684938)
Accepts Healthy Volunteer
N/A

Trial design

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A